• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by RenovoRx Inc.

    3/31/25 5:11:36 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNXT alert in real time by email
    NT 10-K 1 formnt10-k.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

     

    For Period Ended: December 31, 2024_________________________________

     

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

     

    For the Transition Period Ended: _____________________________________

     

    Read Instructions (on back page) Before Preparing Form. Please Print or Type.

     

    NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED

    ANY INFORMATION CONTAINED HEREIN.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    Full Name of Registrant RenovoRx, Inc.
    Former Name if Applicable  
    Address of Principal Executive Office (Street and Number) 2570 W El Camino Real, Suite 320
    City, State and Zip Code Mountain View, CA 94040

     

     

     

       

     

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    The Registrant is unable to file its Form 10-K for the year ended December 31, 2024 within the prescribed time period without unreasonable effort or expense because of the need to complete certain technical accounting requirements with the Registrant’s current and former auditing firms. The Registrant anticipates that it will file its Form 10-K within the fifteen-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

     

    PART IV —OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Shaun R. Bagai   (650)   284-4433
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
       
      ☒ Yes ☐ No
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
       
      ☒ Yes ☐ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    The following changes are anticipated to the Company’s results of operations for the year ended December 31, 2024 as compared to the corresponding period for the last fiscal year:

     

    The Registrant expects to recognize small initial revenue from its RenovoCath commercial efforts for the fiscal year ended December 31, 2024 versus the year ended December 31, 2023 and a small decrease in net loss due in part to a reduction in selling, general, and administrative expenses.

     

    The amounts reported above are still under review by the Registrant’s independent registered public accounting firm and accounting staff and may differ once reported in the Form 10-K to be filed by the Registrant.

     

       

     

     

      RenovoRx, Inc.  
      (Name of Registrant as Specified in Charter)  

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 31, 2025 By: /s/ Ronald B. Kocak
        Ronald B. Kocak
        Vice President, Controller and Principal Accounting Officer

     

       

     

    Get the next $RNXT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNXT

    DatePrice TargetRatingAnalyst
    11/1/2021$16.00Buy
    Roth Capital
    10/6/2021$15.00Buy
    Maxim Group
    More analyst ratings

    $RNXT
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by RenovoRx Inc.

      SCHEDULE 13G - RenovoRx, Inc. (0001574094) (Subject)

      5/8/25 7:44:41 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by RenovoRx Inc.

      SCHEDULE 13G - RenovoRx, Inc. (0001574094) (Subject)

      5/7/25 4:34:20 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by RenovoRx Inc.

      DEF 14A - RenovoRx, Inc. (0001574094) (Filer)

      4/30/25 5:13:07 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Leadership Updates

    Live Leadership Updates

    See more
    • RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

      LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

      6/10/24 8:30:00 AM ET
      $IMMX
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Closes $6.1 Million Private Placement

      With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c

      1/29/24 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre

      11/16/23 8:35:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

      SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

      2/14/23 4:51:34 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RenovoRx Inc.

      SC 13G - RenovoRx, Inc. (0001574094) (Subject)

      4/14/22 2:24:24 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by RenovoRx Inc.

      SC 13G - RenovoRx, Inc. (0001574094) (Subject)

      2/14/22 6:33:04 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

      Patent Expands Protection of TAMP therapy platform, Including Methods to Deliver an Agent, such as a Chemotherapeutic Drug, Near a Tumor RenovoRx Currently Holds a Strong and Growing IP Portfolio with 19 Issued Patents and 12 Pending Patents Supporting the Commercialization of RenovoCath Device RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.

      5/6/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Event: RenovoRx First Quarter 2025 Financial Results Conference Call Date: Thursday, May 15, 2025 Time: 4:30 p.m. ET Live Call: 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International) Webcast:

      5/1/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

      Johns Hopkins Medicine's Valerie Lee, MD joins Michael J. Pishvaian, MD in an Appointed Key Role for TIGeR-PaC Trial By becoming an additional clinical site for TIGeR-PaC, Johns Hopkins Medicine joins several esteemed cancer centers to support RenovoRx's initiative to complete patient enrollment for the trial during 2025 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer (LAPC) in RenovoRx's ongoing Phase III TIGeR

      4/29/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Financials

    Live finance-specific insights

    See more

    $RNXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

      RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Event: RenovoRx First Quarter 2025 Financial Results Conference Call Date: Thursday, May 15, 2025 Time: 4:30 p.m. ET Live Call: 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International) Webcast:

      5/1/25 8:30:00 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on RenovoRx with a new price target

      Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

      11/1/21 11:49:10 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on RenovoRx with a new price target

      Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

      10/6/21 8:24:28 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marton Laurence exercised 20,480 shares at a strike of $0.15, increasing direct ownership by 45% to 66,164 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      5/6/25 4:10:20 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/17/25 6:10:32 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Bagai Shaun

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/16/25 5:18:21 PM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RNXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Agah Ramtin bought $13,500 worth of shares (15,000 units at $0.90), increasing direct ownership by 1% to 1,113,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/17/25 6:10:32 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Bagai Shaun bought $6,821 worth of shares (7,500 units at $0.91), increasing direct ownership by 2% to 320,040 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/16/25 6:08:22 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Agah Ramtin bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 2% to 1,098,460 units (SEC Form 4)

      4 - RenovoRx, Inc. (0001574094) (Issuer)

      4/14/25 6:30:30 AM ET
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care